Soluble Suppression of Tumorigenicity-2 as a Candidate Prognostic Marker for Stroke: A Systematic Review
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Risk stratification of patients for incidence of stroke and its outcomes can aid in decision-making regarding treatment options and rehabilitative care. We systematically reviewed the literature to provide comprehensive evidence for the value of serum soluble suppression of tumorigenicity-2 (sST-2) in the prediction of stroke incidence and the evaluation of post-stroke outcomes. Methods: The Medline, Scopus, Web of Science, and Embase databases were searched until the end of August 2022 for studies investigating the value of serum sST-2 in the prediction of stroke incidence and post-stroke outcomes. Results: Nineteen articles were included. The articles reported conflicting results on the predictive value of sST-2 measurement in the incidence of stroke. Studies investigating the value of sST-2 measurement for the prognosis of post-stroke outcomes have reported positive associations between sST-2 levels and post-stroke mortality, composite adverse events, major disability, cerebral–cardiac syndrome, and cognitive impairment. Conclusions: Although some studies have reported a predictive value of serum sST-2 measurement in the incidence of stroke, a clear consensus has yet to be reached because of discrepancies in the results. As for the prognosis of post-stroke outcomes, sST-2 may be a predictor of mortality, composite adverse events, and major disability after stroke. Overall, more well-designed prospective cohort studies are needed to reach a more decisive conclusion on the value of sST-2 measurement for the prediction of stroke and its outcomes and to determine optimal cutoffs.
Abstract
Background: Risk stratification of patients for incidence of stroke and its outcomes can aid in decision-making regarding treatment options and rehabilitative care. We systematically reviewed the literature to provide comprehensive evidence for the value of serum soluble suppression of tumorigenicity-2 (sST-2) in the prediction of stroke incidence and the evaluation of post-stroke outcomes. Methods: The Medline, Scopus, Web of Science, and Embase databases were searched until the end of August 2022 for studies investigating the value of serum sST-2 in the prediction of stroke incidence and post-stroke outcomes. Results: Nineteen articles were included. The articles reported conflicting results on the predictive value of sST-2 measurement in the incidence of stroke. Studies investigating the value of sST-2 measurement for the prognosis of post-stroke outcomes have reported positive associations between sST-2 levels and post-stroke mortality, composite adverse events, major disability, cerebral–cardiac syndrome, and cognitive impairment. Conclusions: Although some studies have reported a predictive value of serum sST-2 measurement in the incidence of stroke, a clear consensus has yet to be reached because of discrepancies in the results. As for the prognosis of post-stroke outcomes, sST-2 may be a predictor of mortality, composite adverse events, and major disability after stroke. Overall, more well-designed prospective cohort studies are needed to reach a more decisive conclusion on the value of sST-2 measurement for the prediction of stroke and its outcomes and to determine optimal cutoffs.
참고문헌 (40)
- Brott T, "Measurements of acute cerebral infarction : a clinical examination scale", Stroke, 20, pp.864~870 (1989)
- Saenger AK, "Stroke biomarkers: progress and challenges for diagnosis, prognosis, differentiation, and treatment", Clinical Chemistry, 56, pp.21~33 (2010)
- Altara R, "Conflicting vascular and metabolic impact of the IL-33", sST2 axis, 2018, pp.114, 1578~1594
- Seki K, "Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling", Circ Heart Fail, 2, pp.684~691 (2009)
- Zhang J, "Soluble ST2 in coronary artery disease : clinical biomarkers and treatment guidance", Front Cardiovasc Med, 9, pp.924461~ (2022)
- Homsak E, "Soluble ST2 : a complex and diverse role in several diseases", Clin Chim Acta, 507, pp.75~87 (2022)
- Aimo A, "Clinical and prognostic significance of sST2 in heart failure : JACC review topic of the week", J Am Coll Cardiol, 74, pp.2193~2203 (2019)
- Mueller T, "The Presage(®)ST2 assay : analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2", Expert Rev Mol Diagn, 13, pp.13~30 (2013)
- Moher D, "Preferred reporting items for systematic reviews and meta-analyses : the PRISMA statement", PLoS Med, 6, pp.e1000097~ (2009)
- Whiting PF, "QUADAS-2 : a revised tool for the quality assessment of diagnostic accuracy studies", Ann Intern Med, 155, pp.529~536 (2011)
- Schunemann HJ, "Cochrane handbook for systematic reviews of interventions", pp.375~402 (2019), Wiley
- Andersson C, "Associations of circulating growth differentiation factor-15 and ST2 concentrations with subclinical vascular brain injury and incident stroke", Stroke, 46, pp.2568~2575 (2015)
- Bai J, "Combined use of high-sensitivity ST2 and NT-proBNP for predicting major adverse cardiovascular events in coronary heart failure", Ann Palliat Med, 9, pp.1976~1989 (2020)
- Hammer F, "Soluble suppression of tumorigenesis-2 is a strong predictor of all-cause, cardiovascular and infection-related mortality risk in haemodialysis patients with diabetes mellitus", Clin Kidney J, 15, pp.1915~1923 (2022)
- Hijazi Z, "Screening of multiple biomarkers associated with ischemic stroke in atrial fibrillation", J Am Heart Assoc, 9, pp.e018984~ (2020)
- Hughes MF, "ST2 may not be a useful predictor for incident cardiovascular events, heart failure and mortality", Heart, 100, pp.1715~1721 (2014)
- Khamitova AF, "Analysis of distant cardiovascular events depending on the biomarker profile in patients with myocardial infarction", Russ J Cardiol, 24, pp.24~31 (2019)
- Lidgard B, "Cardiac biomarkers and risk of atherosclerotic cardiovascular disease in patients with CKD", Kidney360, 3, pp.859~871 (2022)
- Polineni S, "Predictive ability of novel cardiac biomarkers ST2, galectin-3, and NT-ProBNP before cardiac surgery", J Am Heart Assoc, 7, pp.e008371~ (2018)
- Seo SM, "Prognostic utility of soluble suppression of tumorigenicity 2 level as a predictor of clinical outcomes in incident hemodialysis patients", Int J Med Sci, 15, pp.730~737 (2018)
- Somuncu MU, "Predicting long-term cardiovascular outcomes of patients with acute myocardial infarction using soluble ST2", Horm Mol Biol Clin Investig, 41, pp.20190062~ (2020)
- Dieplinger B, "Prognostic value of inflammatory and cardiovascular biomarkers for prediction of 90-day all-cause mortality after acute ischemic stroke-results from the Linz stroke unit study", Clin Chem, 63, pp.1101~1109 (2017)
- Lu Y, "Plasma soluble suppression of tumorigenicity 2 and depression after acute ischemic stroke", Eur J Neurol, 28, pp.868~876 (2021)
- Mechtouff L, "Prognosis value of serum soluble ST2 level in acute ischemic stroke and STEMI patients in the era of mechanical reperfusion therapy", J Neurol, 269, pp.2641~2648 (2022)
- Sung PH, "Soluble ST2 is a useful biomarker for grading cerebral-cardiac syndrome in patients after acute ischemic stroke", J Clin Med, 9, pp.489~ (2020)
- Tian X, "Serum soluble ST2 is a predictor for poor long-term prognosis after transient ischemic attack and ischemic stroke : a cohort study" (2019)[DOI]
- Tian X, "Serum soluble ST2 is a potential long-term prognostic biomarker for transient ischaemic attack and ischaemic stroke", Eur J Neurol, 27, pp.2202~2208 (2020)
- Wolcott Z, "Soluble ST2 predicts outcome and hemorrhagic transformation after acute stroke", Ann Clin Transl Neurol, 4, pp.553~563 (2017)
- Xu M, "The clinical significance of serum IL-33 and sST2 alterations in the post-stroke depression", J Multidiscip Healthc, 14, pp.2009~2015 (2021)
- Zhu Y, "Soluble ST2 and risk of cognitive impairment after acute ischemic stroke : a prospective observational study", BMC Geriatr, 21, pp.330~ (2021)
- Yancy CW, "2017 ACC", AHA, AHA guideline for the management of heart failure: a report of the American College of Cardiology, pp.American Heart Association Task Force on Clinical Practice guidelines and the Heart Failure Society of America, Circulation[DOI]
- Liu N, "The association between soluble suppression of tumorigenicity-2 and long-term prognosis in patients with coronary artery disease : a meta-analysis", PLoS One, 15, pp.e0238775~ (2020)
- Major RW, "Cardiovascular disease risk factors in chronic kidney disease : a systematic review and meta-analysis", PLoS One, 13, pp.e0192895~ (2018)
- Krishnamoorthy S, "Biomarkers in the prediction of hemorrhagic transformation in acute stroke : a systematic review and meta-analysis", Cerebrovasc Dis, 51, pp.235~247 (2022)
- Gadani SP, "The glia-derived alarmin IL-33 orchestrates the immune response and promotes recovery following CNS injury", Neuron, 85, pp.703~709 (2015)
- Luo Y, "Interleukin-33 ameliorates ischemic brain injury in experimental stroke through promoting Th2 response and suppressing Th17 response", Brain Res, 1597, pp.86~94 (2015)
- Xu J, "IL-4", STAT6 signaling facilitates innate hematoma resolution and neurological recovery after hemorrhagic stroke in mice, 2020, pp.117, 32679~32690
- Zhang SR, "IL-33 modulates inflammatory brain injury but exacerbates systemic immunosuppression following ischemic stroke", JCI Insight, 3, pp.e121560~ (2018)
- Yang Y, "Blood-brain barrier breakdown in acute and chronic cerebrovascular disease", Stroke, 42, pp.3323~3328 (2011)
- Boisot S, "Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure", J Card Fail, 14, pp.732~738 (2008)